Bicycle Therapeutics: Westfield reports 0 shares
Bicycle Therapeutics plc received an amended Schedule 13G/A filing from Westfield Capital Management Company, L.P. reporting 0 shares beneficially owned of common stock, representing 0% as of 12/31/2025.
Rhea-AI Filing Summary
Bicycle Therapeutics plc received an amended Schedule 13G/A filing from Westfield Capital Management Company, L.P. reporting 0 shares beneficially owned of common stock, representing 0% as of 12/31/2025. The amendment is signed by Brandi McMahon, Vice President, Deputy Chief Compliance Officer, dated 03/03/2026.
Positive
- None.
Negative
- None.
Insights
Amendment confirms no beneficial ownership as of the reporting date.
The filing is an amended Schedule 13G/A from Westfield Capital Management Company, L.P. stating 0 shares and 0% ownership as of 12/31/2025. This is a routine ownership disclosure update rather than a transaction.
Timing and signature are shown: signed by Brandi McMahon on 03/03/2026. Subsequent filings would show any change in holdings.
Disclosure indicates no reportable stake, limiting immediate governance influence.
The schedule explicitly lists zero votes and zero dispositive power for Westfield across all categories, consistent with ownership of 5 percent or less disclosures. This filing does not alter board composition or shareholder voting dynamics.
Investors seeking changes in ownership should watch future amendments or Section 13 filings for updated share counts and percentages.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Westfield Capital report in the BCYC Schedule 13G/A?
Does the Schedule 13G/A indicate any voting or dispositive power for Westfield Capital?
Who signed the amended Schedule 13G/A for BCYC and when?
Is this Schedule 13G/A a transaction filing for BCYC?
AI-generated analysis. How Rhea-AI works. Not financial advice.